Sign Out
Syndopa 275 permits more levodopa to reach the brain and thus dyskinesias may occur at lower dosage and sooner as compared to levodopa therapy. Monoamine oxidase inhibitors, if taken by patients, must be discontinued at least 2 weeks prior to institution of Syndopa 275 therapy.
As with levodopa, periodic evaluations of hepatic, hematopoietic, cardiovascular and renal function are recommended during extended therapy with Syndopa 275. The occurrence of blepharospasm is a sign of overdosage with Syndopa 275.
Continue with Google